A Study Examining Torcetrapib/Atorvastatin And Atorvastatin Effects On Clinical CV Events In Patients With Heart Disease (ILLUMINATE)

This study has been terminated.
Sponsor:
Information provided by (Responsible Party):
Pfizer
ClinicalTrials.gov Identifier:
NCT00134264
First received: August 22, 2005
Last updated: January 30, 2012
Last verified: January 2012
  Purpose

The Torcetrapib project was terminated on December 2, 2006 due to safety findings.

To demonstrate if torcetrapib/atorvastatin can reduce the risk for major cardiovascular disease events, when compared to atorvastatin alone, in patients with coronary heart disease or risk equivalents


Condition Intervention Phase
Coronary Disease
Diabetes Mellitus
Drug: torcetrapib/atorvastatin
Drug: atorvastatin
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: Phase 3 Multi Center, Double Blind, Randomized, Parallel Group Evaluation Of The Fixed Combination Torcetrapib/Atorvastatin, Administered Orally, Once Daily (Qd), Compared With Atorvastatin Alone, On The Occurrence Of Major Cardiovascular Events In Subjects With Coronary Heart Disease Or Risk Equivalents

Resource links provided by NLM:


Further study details as provided by Pfizer:

Primary Outcome Measures:
  • The time to first occurrence of a major cardiovascular disease event

Secondary Outcome Measures:
  • Various composites of major cardiovascular disease events and other lipid parameters

Enrollment: 15067
Study Start Date: July 2004
Study Completion Date: June 2007
Primary Completion Date: June 2007 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   45 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Diagnosis of coronary heart disease or risk equivalents that place the patient at high risk for cardiovascular disease events

Exclusion Criteria:

  • Women who are pregnant or lactating, or planning to become pregnant.
  • Subjects with a clinically indicated need for statin (HMG-CoA reductase inhibitor) therapy other than atorvastatin or other concomitant therapy with known lipid altering effects on LDL-C and HDL-C including fibrates and nicotinic acid
  • Subjects taking any drugs known to be associated with an increased risk of myositis in combination with HMG-CoA reductase inhibitors
  • Subjects with any other medical condition or laboratory abnormality which could affect subject safety, preclude evaluationof response, or render unlikely that the subject would complete the study
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00134264

  Hide Study Locations
Locations
United States, Alabama
Pfizer Investigational Site
Alabaster, Alabama, United States
Pfizer Investigational Site
Birmingham, Alabama, United States
United States, Arizona
Pfizer Investigational Site
Gilbert, Arizona, United States
Pfizer Investigational Site
Phoenix, Arizona, United States
Pfizer Investigational Site
Tucson, Arizona, United States
United States, California
Pfizer Investigational Site
Fresno, California, United States
Pfizer Investigational Site
Los Angeles, California, United States
Pfizer Investigational Site
Modesto, California, United States
Pfizer Investigational Site
San Diego, California, United States
Pfizer Investigational Site
Santa Rosa, California, United States
Pfizer Investigational Site
Tustin, California, United States
Pfizer Investigational Site
Walnut Creek, California, United States
United States, Colorado
Pfizer Investigational Site
Denver, Colorado, United States
Pfizer Investigational Site
Longmont, Colorado, United States
United States, Connecticut
Pfizer Investigational Site
Guilford, Connecticut, United States
Pfizer Investigational Site
Hartford, Connecticut, United States
United States, District of Columbia
Pfizer Investigational Site
Washington, District of Columbia, United States
United States, Florida
Pfizer Investigational Site
Clearwater, Florida, United States
Pfizer Investigational Site
Coral Gables, Florida, United States
Pfizer Investigational Site
Fort Meyers, Florida, United States
Pfizer Investigational Site
Jacksonville, Florida, United States
Pfizer Investigational Site
Jacksonville Beach, Florida, United States
Pfizer Investigational Site
Lakeland, Florida, United States
Pfizer Investigational Site
Orlando, Florida, United States
Pfizer Investigational Site
Pensacola, Florida, United States
Pfizer Investigational Site
Port Charlotte, Florida, United States
Pfizer Investigational Site
Sarasota, Florida, United States
Pfizer Investigational Site
West Palm Beach, Florida, United States
United States, Georgia
Pfizer Investigational Site
Atlanta, Georgia, United States
United States, Illinois
Pfizer Investigational Site
Aurora, Illinois, United States
Pfizer Investigational Site
Blue Island, Illinois, United States
Pfizer Investigational Site
Chicago, Illinois, United States
United States, Indiana
Pfizer Investigational Site
Evansville, Indiana, United States
Pfizer Investigational Site
Fort Wayne, Indiana, United States
United States, Iowa
Pfizer Investigational Site
Davenport, Iowa, United States
Pfizer Investigational Site
des Moines, Iowa, United States
Pfizer Investigational Site
Iowa City, Iowa, United States
United States, Kansas
Pfizer Investigational Site
Wichita, Kansas, United States
Pfizer Investigational Site
Witchita, Kansas, United States
United States, Kentucky
Pfizer Investigational Site
Louisville, Kentucky, United States
United States, Louisiana
Pfizer Investigational Site
Baton Rouge, Louisiana, United States
Pfizer Investigational Site
Covington, Louisiana, United States
Pfizer Investigational Site
Marrero, Louisiana, United States
United States, Maine
Pfizer Investigational Site
Scarborough, Maine, United States
United States, Maryland
Pfizer Investigational Site
Baltimore, Maryland, United States
Pfizer Investigational Site
Bel Air, Maryland, United States
Pfizer Investigational Site
Columbia, Maryland, United States
Pfizer Investigational Site
Towson, Maryland, United States
Pfizer Investigational Site
Westminster, Maryland, United States
United States, Massachusetts
Pfizer Investigational Site
Abington, Massachusetts, United States
Pfizer Investigational Site
Haverhill, Massachusetts, United States
Pfizer Investigational Site
Natick, Massachusetts, United States
United States, Michigan
Pfizer Investigational Site
Grand Rapids, Michigan, United States
United States, Minnesota
Pfizer Investigational Site
Minneapolis, Minnesota, United States
Pfizer Investigational Site
St. Paul, Minnesota, United States
United States, Missouri
Pfizer Investigational Site
St. Louis, Missouri, United States
United States, Montana
Pfizer Investigational Site
Billings, Montana, United States
Pfizer Investigational Site
Butte, Montana, United States
United States, Nebraska
Pfizer Investigational Site
Omaha, Nebraska, United States
Pfizer Investigational Site
Papillon, Nebraska, United States
United States, Nevada
Pfizer Investigational Site
Las Vegas, Nevada, United States
United States, New Hampshire
Pfizer Investigational Site
Concord, New Hampshire, United States
Pfizer Investigational Site
Lebanon, New Hampshire, United States
Pfizer Investigational Site
Manchester, New Hampshire, United States
United States, New Jersey
Pfizer Investigational Site
Elmer, New Jersey, United States
Pfizer Investigational Site
Haddon Heights, New Jersey, United States
Pfizer Investigational Site
New Brunswick, New Jersey, United States
United States, New York
Pfizer Investigational Site
Garden City, New York, United States
Pfizer Investigational Site
New Hyde Park, New York, United States
Pfizer Investigational Site
Rochester, New York, United States
United States, North Carolina
Pfizer Investigational Site
Durham, North Carolina, United States
Pfizer Investigational Site
Winston-salem, North Carolina, United States
United States, Ohio
Pfizer Investigational Site
Cincinnati, Ohio, United States
Pfizer Investigational Site
Cleveland, Ohio, United States
Pfizer Investigational Site
Columbus, Ohio, United States
Pfizer Investigational Site
Mansfield, Ohio, United States
Pfizer Investigational Site
Sandusky, Ohio, United States
Pfizer Investigational Site
Toledo, Ohio, United States
United States, Oklahoma
Pfizer Investigational Site
Oklahoma City, Oklahoma, United States
United States, Oregon
Pfizer Investigational Site
Portland, Oregon, United States
United States, Pennsylvania
Pfizer Investigational Site
Beaver, Pennsylvania, United States
Pfizer Investigational Site
Philadelphia, Pennsylvania, United States
United States, Tennessee
Pfizer Investigational Site
Kingsport, Tennessee, United States
Pfizer Investigational Site
Nashville, Tennessee, United States
United States, Texas
Pfizer Investigational Site
Beaumont, Texas, United States
Pfizer Investigational Site
Dallas, Texas, United States
Pfizer Investigational Site
Houston, Texas, United States
Pfizer Investigational Site
Plano, Texas, United States
Pfizer Investigational Site
San Antonio, Texas, United States
United States, Utah
Pfizer Investigational Site
Salt Lake City, Utah, United States
United States, Vermont
Pfizer Investigational Site
Burlington, Vermont, United States
United States, Virginia
Pfizer Investigational Site
Norfolk, Virginia, United States
Pfizer Investigational Site
Richmond, Virginia, United States
United States, Washington
Pfizer Investigational Site
Burien, Washington, United States
Pfizer Investigational Site
Tacoma, Washington, United States
Australia, New South Wales
Pfizer Investigational Site
Concord, New South Wales, Australia
Pfizer Investigational Site
East Gosford, New South Wales, Australia
Pfizer Investigational Site
St. Leonards, New South Wales, Australia
Pfizer Investigational Site
Wollongong, New South Wales, Australia
Australia, Queensland
Pfizer Investigational Site
Chermside, Queensland, Australia
Pfizer Investigational Site
Herston, Queensland, Australia
Pfizer Investigational Site
Woolloongabba, Queensland, Australia
Australia, South Australia
Pfizer Investigational Site
Adelaide, South Australia, Australia
Pfizer Investigational Site
Bedford Park, South Australia, Australia
Pfizer Investigational Site
Woodville, South Australia, Australia
Australia, Victoria
Pfizer Investigational Site
Clayton, Victoria, Australia
Pfizer Investigational Site
Fitzroy, Victoria, Australia
Pfizer Investigational Site
Footscray, Victoria, Australia
Pfizer Investigational Site
Heidelberg, Victoria, Australia
Pfizer Investigational Site
Prahran, Victoria, Australia
Australia, Western Australia
Pfizer Investigational Site
Fremantle, Western Australia, Australia
Pfizer Investigational Site
Joondalup, Western Australia, Australia
Australia
Pfizer Investigational Site
Camperdown, Australia
Pfizer Investigational Site
Darlinghurst, Australia
Pfizer Investigational Site
Geelong, Australia
Pfizer Investigational Site
Launceston, Tas, Australia
Pfizer Investigational Site
Melbourne, Australia
Pfizer Investigational Site
Nedlands, Australia
Pfizer Investigational Site
Perth, Australia
Pfizer Investigational Site
Southport, Australia
Canada, Alberta
Pfizer Investigational Site
Calgary, Alberta, Canada
Canada, British Columbia
Pfizer Investigational Site
Vancouver, British Columbia, Canada
Canada, Manitoba
Pfizer Investigational Site
Winnipeg, Manitoba, Canada
Canada, Nova Scotia
Pfizer Investigational Site
Halifax, Nova Scotia, Canada
Canada, Ontario
Pfizer Investigational Site
Cornwall, Ontario, Canada
Pfizer Investigational Site
Newmarket, Ontario, Canada
Pfizer Investigational Site
Oshawa, Ontario, Canada
Pfizer Investigational Site
Sarnia, Ontario, Canada
Pfizer Investigational Site
Scarborough, Ontario, Canada
Pfizer Investigational Site
Toronto, Ontario, Canada
Canada, Quebec
Pfizer Investigational Site
Laval, Quebec, Canada
Pfizer Investigational Site
Montreal, Quebec, Canada
Pfizer Investigational Site
Sainte-foy, Quebec, Canada
Pfizer Investigational Site
Sherbrooke, Quebec, Canada
Pfizer Investigational Site
Ste-foy, Quebec, Canada
Canada
Pfizer Investigational Site
Saint John's, Canada
Netherlands
Pfizer Investigational Site
Amsterdam, Netherlands
Pfizer Investigational Site
AN Rotterdam, Netherlands
Pfizer Investigational Site
Apeldoorn, Netherlands
Pfizer Investigational Site
Arnhem, Netherlands
Pfizer Investigational Site
Breda, Netherlands
Pfizer Investigational Site
Cappelle aan den IJssel, Netherlands
Pfizer Investigational Site
Delft, Netherlands
Pfizer Investigational Site
Eindhoven, Netherlands
Pfizer Investigational Site
Goes, Netherlands
Pfizer Investigational Site
Gouda, Netherlands
Pfizer Investigational Site
Groningen, Netherlands
Pfizer Investigational Site
Heerlen, Netherlands
Pfizer Investigational Site
Hertogenbosch, Netherlands
Pfizer Investigational Site
Hoorn, Netherlands
Pfizer Investigational Site
Leiden, Netherlands
Pfizer Investigational Site
Maastricht, Netherlands
Pfizer Investigational Site
Nijmegen, Netherlands
Pfizer Investigational Site
Rotterdam, Netherlands
Pfizer Investigational Site
Sittard, Netherlands
Pfizer Investigational Site
Utrecht, Netherlands
Pfizer Investigational Site
Velp, Netherlands
Pfizer Investigational Site
Venlo, Netherlands
Pfizer Investigational Site
Zoetermeer, Netherlands
Spain
Pfizer Investigational Site
Sant Coloma de Gramenet, Barcelona, Spain
Pfizer Investigational Site
Terrasa, Barcelona, Spain
Pfizer Investigational Site
Jerez de La Frontera, Cadiz, Spain
Pfizer Investigational Site
Santander, Cantabria, Spain
Pfizer Investigational Site
San Sebastian, Guipuzcoa, Spain
Pfizer Investigational Site
Ferrol, La Coruna, Spain
Pfizer Investigational Site
Santiago De Compostela, La Coruña, Spain
Pfizer Investigational Site
Almeria, Spain
Pfizer Investigational Site
Barcelona, Spain
Pfizer Investigational Site
Ciudad Real, Spain
Pfizer Investigational Site
Granada, Spain
Pfizer Investigational Site
Madrid, Spain
Pfizer Investigational Site
Malaga, Spain
Pfizer Investigational Site
Salamanca, Spain
Pfizer Investigational Site
Sevilla, Spain
Pfizer Investigational Site
Valencia, Spain
Pfizer Investigational Site
Zaragoza, Spain
Sweden
Pfizer Investigational Site
Borås, Sweden
Pfizer Investigational Site
Eskilstuna, Sweden
Pfizer Investigational Site
Goteborg, Sweden
Pfizer Investigational Site
Göteborg, Sweden
Pfizer Investigational Site
Helsingborg, Sweden
Pfizer Investigational Site
Hässleholm, Sweden
Pfizer Investigational Site
Karlshamn, Sweden
Pfizer Investigational Site
Koping, Sweden
Pfizer Investigational Site
Linköping, Sweden
Pfizer Investigational Site
Lulea, Sweden
Pfizer Investigational Site
Lund, Sweden
Pfizer Investigational Site
Malmo, Sweden
Pfizer Investigational Site
Molndal, Sweden
Pfizer Investigational Site
Norrkoping, Sweden
Pfizer Investigational Site
Ostersund, Sweden
Pfizer Investigational Site
Skelleftea, Sweden
Pfizer Investigational Site
Stockholm, Sweden
Pfizer Investigational Site
Uddevalla, Sweden
Pfizer Investigational Site
Uppsala, Sweden
Pfizer Investigational Site
Vaxjo, Sweden
Pfizer Investigational Site
Västervik, Sweden
United Kingdom
Pfizer Investigational Site
Wrexham, Clwyd, United Kingdom
Pfizer Investigational Site
Woolwich, London, United Kingdom
Pfizer Investigational Site
Glasgow, Scotland, United Kingdom
Pfizer Investigational Site
Aberdeen, United Kingdom
Pfizer Investigational Site
Bath, United Kingdom
Pfizer Investigational Site
Birmingham, United Kingdom
Pfizer Investigational Site
Bournemouth, United Kingdom
Pfizer Investigational Site
Brighton, East Sussex, United Kingdom
Pfizer Investigational Site
Bristol, United Kingdom
Pfizer Investigational Site
Cardiff, United Kingdom
Pfizer Investigational Site
Chichester, United Kingdom
Pfizer Investigational Site
Coventry, United Kingdom
Pfizer Investigational Site
Dundee, United Kingdom
Pfizer Investigational Site
Edinburgh, United Kingdom
Pfizer Investigational Site
Exeter, United Kingdom
Pfizer Investigational Site
Glasgow, United Kingdom
Pfizer Investigational Site
Harrow, United Kingdom
Pfizer Investigational Site
Leicester, United Kingdom
Pfizer Investigational Site
Liverpool, United Kingdom
Pfizer Investigational Site
London, United Kingdom
Pfizer Investigational Site
Newcastle-upon-Tyne, United Kingdom
Pfizer Investigational Site
Romford, United Kingdom
Pfizer Investigational Site
Shrewsbury, United Kingdom
Pfizer Investigational Site
Warwick, United Kingdom
Sponsors and Collaborators
Pfizer
Investigators
Study Director: Pfizer CT.gov Call Center Pfizer
  More Information

Additional Information:
No publications provided by Pfizer

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Responsible Party: Pfizer
ClinicalTrials.gov Identifier: NCT00134264     History of Changes
Other Study ID Numbers: A5091043
Study First Received: August 22, 2005
Last Updated: January 30, 2012
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Coronary Disease
Coronary Artery Disease
Diabetes Mellitus
Heart Diseases
Myocardial Ischemia
Cardiovascular Diseases
Vascular Diseases
Arteriosclerosis
Arterial Occlusive Diseases
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Atorvastatin
Torcetrapib
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Anticholesteremic Agents
Hypolipidemic Agents
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Enzyme Inhibitors
Lipid Regulating Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on July 29, 2014